Administration of lactoferrin capsules (Mosiac, Pharmaguida) alone in asymptomatic patients, or in combination with other drugs in paucysymptomatic or moderately symptomatic patients, may be an effective treatment without adverse effects in the management of SARS-CoV-2 infection. . This is what one says Italian clinical study on the oral administration of lactoferrin in a hundred patients affected by Covid-19, published in September in the “Journal of Clinical Medicine”.
“Beyond the indisputable efficacy of anti-SARS-CoV-2 vaccines, the great spread of the infection associated with this coronavirus also requires the availability of antiviral agents. Lactoferrin – explains Piera Valenti, Full Professor of Microbiology at the University of Rome La Sapienza and Member of the International Committee of Experts on Lactoferrin – it is known to have an antiviral activity. In fact, when it is in contact with the virus, it prevents its entry into the cell and therefore its replication. Furthermore, lactoferrin has a powerful anti-inflammatory and anti-thrombotic activity, essential functions in the treatment of Covid-19 ″.
RESULTS OF THE STUDY – “In this retrospective clinical study, the timely oral administration of lactoferrin proved useful in Covid patients. The first relevant data – the study reads – concerns the time required to obtain the negativization of the molecular buffer in the 82 patients treated with lactoferrin, a time that was significantly lower than that observed in the 39 untreated patients (15 instead of 24 days). Furthermore, none of the patients belonging to the group treated with lactoferrin was hospitalized. Asymptomatic, paucisymptomatic and moderately symptomatic patients were treated with a different number of capsules (1 to 5) each containing 200 mg of lactoferrin (Mosiac, Pharmaguida) depending on the severity of Covid-19. The results also highlight the existence – say the researchers – of a link between the greater efficacy of treatment with lactoferrin, the significant reduction in symptoms and age. In fact, lactoferrin is synthesized under hormonal control and its production decreases with advancing age. It follows that, in older subjects who synthesize a smaller amount, the supplementation of the exogenous protein shows greater efficacy than that observed in younger patients. The study comes after two international publications appeared in June 2021 in Frontiers in Pharmacology and in August 2021 in PNAS concerning the efficacy of lactoferrin in vitro in inhibiting Covid-192 infection “.
“This publication and these data are very interesting – he comments Paolo Manzoni, director of Pediatrics and Neonatology of the ASL of Biella – make even more significant the prospective randomized study against placebo and double-blind that we conducted with the same product and that we have just completed in Biella and Novara, to evaluate whether lactoferrin can give clinical benefits in patients already hospitalized for Covid-19. The results, which will be made public shortly, could further integrate and complete those available today regarding a possible anti-Covid-19 action of lactoferrin itself “.